Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. More Details
Flawless balance sheet with concerning outlook.
Share Price & News
How has Medicenna Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MDNA is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: MDNA's weekly volatility has decreased from 13% to 8% over the past year.
7 Day Return
1 Year Return
Return vs Industry: MDNA exceeded the Canadian Biotechs industry which returned 76.8% over the past year.
Return vs Market: MDNA exceeded the Canadian Market which returned -0.5% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Medicenna Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StCompanies Like Medicenna Therapeutics (TSE:MDNA) Can Afford To Invest In Growth
5 months ago | Simply Wall StWho Has Been Buying Medicenna Therapeutics Corp. (TSE:MDNA) Shares?
6 months ago | Simply Wall StWhat Kind Of Shareholder Appears On The Medicenna Therapeutics Corp.'s (TSE:MDNA) Shareholder Register?
Is Medicenna Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MDNA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MDNA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MDNA is unprofitable, so we can't compare its PE Ratio to the XN Biotechs industry average.
PE vs Market: MDNA is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MDNA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MDNA is overvalued based on its PB Ratio (7x) compared to the CA Biotechs industry average (6.2x).
How is Medicenna Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MDNA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MDNA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MDNA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if MDNA's revenue is forecast to grow faster than the Canadian market.
High Growth Revenue: Insufficient data to determine if MDNA's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MDNA's Return on Equity is forecast to be very high in 3 years time (49%).
How has Medicenna Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MDNA is currently unprofitable.
Growing Profit Margin: MDNA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MDNA is unprofitable, and losses have increased over the past 5 years at a rate of 17.6% per year.
Accelerating Growth: Unable to compare MDNA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MDNA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.8%).
Return on Equity
High ROE: MDNA has a negative Return on Equity (-31.17%), as it is currently unprofitable.
How is Medicenna Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: MDNA's short term assets (CA$37.5M) exceed its short term liabilities (CA$1.6M).
Long Term Liabilities: MDNA's short term assets (CA$37.5M) exceed its long term liabilities (CA$13.0K).
Debt to Equity History and Analysis
Debt Level: MDNA is debt free.
Reducing Debt: MDNA has no debt compared to 5 years ago when its debt to equity ratio was 65.5%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MDNA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MDNA has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 19.2% each year.
What is Medicenna Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MDNA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MDNA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MDNA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MDNA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MDNA's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Fahar Merchant (63 yo)
Dr. Fahar Merchant, Ph.D. serves as the Chairman, Chief Executive Officer and President at A2 Acquisition Corp. Dr. Merchant has been President and Chief Executive Officer and Director of Medicenna Therape...
CEO Compensation Analysis
Compensation vs Market: Fahar's total compensation ($USD539.31K) is about average for companies of similar size in the Canadian market ($USD649.66K).
Compensation vs Earnings: Fahar's compensation has increased whilst the company is unprofitable.
|CFO & Corporate Secretary||3.92yrs||CA$370.50k||0.011% |
|Chief Clinical Advisor||no data||no data||no data|
|Head of Clinical Development||no data||no data||no data|
|Scientific Advisor||3.33yrs||no data||no data|
Experienced Management: MDNA's management team is considered experienced (4.3 years average tenure).
|Director||0.17yr||no data||no data|
|Independent Director||1.17yrs||CA$91.40k||0.051% |
|Lead Independent Director||no data||CA$97.90k||0.0031% |
|Non-Executive Independent Director||4yrs||CA$88.90k||0.46% |
Experienced Board: MDNA's board of directors are considered experienced (4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 43.5%.
Medicenna Therapeutics Corp.'s company bio, employee growth, exchange listings and data sources
- Name: Medicenna Therapeutics Corp.
- Ticker: MDNA
- Exchange: TSX
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$245.484m
- Shares outstanding: 49.00m
- Website: https://www.medicenna.com
Number of Employees
- Medicenna Therapeutics Corp.
- 2 Bloor Street West
- 7th Floor
- M4W 3E2
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MDNA||TSX (The Toronto Stock Exchange)||Yes||Common Shares||CA||CAD||Mar 2017|
|MDNA||NasdaqCM (Nasdaq Capital Market)||Yes||Common Shares||US||USD||Mar 2017|
Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interle...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/26 23:47|
|End of Day Share Price||2020/11/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.